Defining the role of platelet glycoprotein receptor inhibitors in STEMI: Focus on tirofiban

Drugs

Volumn 69, Issue 1, 2009, Pages 85-100

  Van't Hof, Arnoud W J ^a,c   Valgimigli, Marco ^b  

^a Isala Klinieken ^*  (Netherlands)

^b UNIVERSITY OF FERRARA   (Italy)

^c ISALA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; RETEPLASE; TIROFIBAN;

BLEEDING; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG ELUTING STENT; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; ST SEGMENT ELEVATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT DURATION; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; TIME FACTORS; TYROSINE;

EID: 59749099401     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200969010-00006     Document Type: Review

References (79)

1. DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980 Oct 16; 303: 897-902
2. Wilson RF, Laxson DD, Lesser JR, et al. Intense microvascular constriction after angioplasty of acute thrombotic coronary arterial lesions. Lancet 1989 Apr 15; I (8642): 807-11
3. Kotani J, Mintz GS, Pregowski J, et al. Volumetric intravascular ultrasound evidence that distal embolization during acute infarct intervention contributes to inadequate myocardial perfusion grade. Am J Cardiol 2003 Sep 15; 92: 728-32
4. Ito H, Okamura A, Iwakura K, et al. Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circulation 1996 Jun 1; 93: 1993-9
5. Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial infarction. Circulation 2007 Nov 27; 116 (22): 2634-53
6. Simes RJ, Topol EJ, Holmes Jr DR, et al., for the GUSTO-I Investigators. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion: importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. Circulation 1995 Apr 1; 91 (7): 1923-8
7. Anderson JL, Karagounis LA, Califf RM. Meta-analysis of five reported studies on the relation of early coronary patency grades with mortality and outcomes after acute myocardial infarction. Am J Cardiol 1996 Jul 1; 78: 1-8
8. Zeymer U, Schroder R, Machnig T, et al. Primary percutaneous transluminal coronary angioplasty accelerates early myocardial reperfusion compared to thrombolytic therapy in patients with acute myocardial infarction. Am Heart J 2003 Oct; 146: 686-91
9. European Cooperative Study Group for Streptokinase Treatment in Acute Myocardial Infarction. Streptokinase in acute myocardial infarction. N Engl JMed 1979 Oct 11; 301 (15): 797-802
10. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1997 Jun 5; 336 (23): 1621-8
11. Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1993 Mar 11; 328 (10): 673-9
12. Zijlstra F, de Boer MJ, Hoorntje J, et al. Comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. New Engl J Med 1993 Mar 11; 328 (10): 680-4
13. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003 Jan 4; 361 (9351): 13-20
14. Van de Werf F, Ardissino D, Betriu A, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2003 Jan; 24 (1): 28-66
15. Van de Werf F. Optimal management of ST-elevation myocardial infarction patients on both sides of the Atlantic. European Society of Cardiology Congress; 2008 Aug 30-Sep 3; Munich
16. Antman EM, Hand M, Armstrong PW, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 writing group to review new evidence and update the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction, writing on behalf of the 2004 writing committee. Circulation 2008 Jan 15; 117 (2): 296-329
17. De Luca G, Suryapranata H, Ottervanger JP, et al. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation 2004 Mar 16; 109:1223-5
18. De Luca G, van 't Hof AW, de Boer MJ, et al. Time-totreatment significantly affects the extent of ST-segment resolution and myocardial blush in patients with acute myocardial infarction treated by primary angioplasty. Eur Heart J 2004 Jun; 25 (12): 1009-13
19. Nallamothu B, Fox KA, Kennelly BM, et al. Relationship of treatment delays and mortality in patients undergoing fibrinolysis and primary percutaneous coronary intervention. The Global Registry of Acute Coronary Events. Heart 2007 Dec; 93 (12): 1552-5
20. Colman RW, Clowes AW, George JN, et al. Overview of hemostasis. In: Colman RW, Marder VJ, Clowes AW, et al., editors. Hemostasis and thrombosis. 4th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2001: 3-16
21. Steinhubl SR, Talley JD, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001 May 29; 103: 2572-8
22. Campo G, Valgimigli M, Gemmati D, et al. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY study. J Am Coll Cardiol 2006 Dec 5; 48 (11): 2178-85
23. Svilaas T, Vlaar PJ, van der Horst IC, et al. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med 2008 Feb 7; 358: 557-67
24. Phillips DR, Charo IF, Prise LV, et al. The platelet membrane glycoprotein IIb-IIIa complex. Blood 1988 Apr; 71: 831-43
25. Tcheng JE, Ellis SG, George BS, et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994 Oct; 90 (4): 1757-64
26. Montalescot G, Barragan P, Wittenberg O, et al. Abciximab before direct angioplasty and stenting in myocardial infarction regarding acute and long-term follow-up: platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001 Jun 21; 344 (25): 1895-903
27. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting with or without abciximab, in acute myocardial infarction. N Engl J Med 2002 Mar 28; 346 (13): 957-66
28. Antoniucci D, Rodriguez A, Hempel A, et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol 2003 Dec 3; 42 (11): 1879-85
29. Antoniucci D, Migliorini A, Parodi G, et al. Abciximab-supported infarct artery stent implantation for acute myocardial infarction and long-term survival: a prospective, multicenter, randomized trial comparing infarct artery stenting plus abciximab with stenting alone. Circulation 2004 Apr 13; 109 (14): 1704-6
30. De Luca G, Suryapranata H, Stone GW, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 2005 Apr 13; 293 (14): 1759-65
31. Montalescot G, Antoniucci D, Kastrati A, et al. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. Eur Heart J 2007 Feb; 28 (4): 443-9
32. Scarborough RM, Kleiman NS, Phillips DR. Platelet glycoprotein IIb/IIIa antagonists: what are the relevant issues concerning their pharmacology and clinical use? Circulation 1999 Jul 27; 100: 437-44
33. Peerlinck K, De Lepeleire I, Goldberg M, et al. MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man. Circulation 1993 Oct; 88 (4 Pt 1): 1512-7
34. Mascelli MA, Lance ET, Damaraju L, et al. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 1998 May 5; 97 (17): 1680-8
35. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998 May 21; 338 (21): 1498-505
36. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998 May 21; 338 (21): 1488-97
37. Bolognese L, Falsini G, Liistro F, et al. Randomized comparison of upstream versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial. J Am Coll Cardiol 2006 Feb 7; 47: 522-8
38. The RESTORE (Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis) Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997 Sep 2; 96 (5): 1445-53
39. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001 Jun 21; 344 (25):1888-94
40. Kabbani SS, Aggarwal A, Terrien EF, et al. Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions. Am J Cardiol 2002 Mar 1; 89 (5): 647-50
41. Schneider DJ, Herrmann HC, Lakkis N, et al. Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban. Am J Cardiol 2002 Dec 15; 90 (12): 1421-3
42. Ernst NMSKJ, Suryapranata H, Miedema K, et al. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction. J Am Coll Cardiol 2004 Sep 15; 44: 1187-93
43. van Werkum JW, Gerritsen WBM, Kelder JC, et al. Inhibition of platelet function by abciximab or high-dose tirofiban in patients with STEMI undergoing primary PCI: a randomised trial. Neth Heart J 2007 Nov; 15 (11): 375-81
44. Cutlip DE, Ricciardi MJ, Ling FS, et al. Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction. Am J Cardiol 2003 Oct 15; 92: 977-80
45. Lee DP, Herity NA, Hiatt BL, et al. Tirofiban given in the emergency room before primary angioplasty. Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) pilot trial. Circulation 2003 Mar 25; 107 (11): 1497-501
46. van 't Hof AW, Ernst N, de Boer MJ, et al. Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial. Eur Heart J 2004 May; 25 (10): 837-46
47. De Luca G, Smit JJ, Ernst N, et al. Impact of adjunctive tirofiban administration on myocardial perfusion and mortality in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. Thromb Haemost 2005 May; 93 (5): 820-3
48. Emre A, Ucer E, Yesilcimen K, et al. Impact of early tirofiban administration on myocardial salvage in patients with acute myocardial infarction undergoing infarct-related artery stenting. Cardiology 2006; 106 (4): 264-9
49. Valgimigli M, Percoco G, Malagutti P, et al. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 2005 May 4; 293 (17): 2109-17
50. Danzi GB, Sesana M, Capuano C, et al. Comparison in patients having primary coronary angioplasty of abciximab versus tirofiban on recovery of left ventricular function. Am J Cardiol 2004 Jul 1; 94 (1): 35-9
51. Shen J, Zhang Q, Zhang RY, et al. Clinical benefits of adjunctive tirofiban therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Coron Artery Dis 2008 Jun; 19 (4): 271-7
52. Fu XH, Hao QQ, Jia XW, et al. Effect of tirofiban plus clopidogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction. Chin Med J 2008 Mar 20; 121 (6): 522-7
53. Valgimigli M, Campo G, Percoco G, et al. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. JAMA 2008 Apr 16; 299 (15): 1788-99
54. van 't Hof AW, Hamm C, Rasoul S, et al. Ongoing tirofiban in myocardial infarction evaluation (On-TIME) 2 trial: rationale and study design. EuroInterv 2007; 3: 371-80
55. Hamm C, van 't Hof AW, ten Berg J, et al. Results of the On-TIME 2 trial: prehospital tirofiban in STEMI [abstract no. 413-5]. American College of Cardiology 57th Annual Scientific Sessions; 2008 Mar 29-Apr 1; Chicago (IL)
56. van 't Hof AW, Ten Berg J, Heestermans T, et al. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME) 2: a multicentre, double-blind, randomised controlled trial. Lancet 2008 Aug 16; 372 (9638): 537-46
57. Dalby M, Bouzamondo A, Lechat P, et al. Transfer for primary angioplasty versus immediate thrombolysis in acute myocardial infarction: a meta-analysis. Circulation 2003 Oct 14; 108: 1809-14
58. Montalescot G. Mechanical reperfusion: treat well, treat on time too. Lancet 2008 Aug 16; 372 (9638): 509-10
59. De Luca G, Gibson M, Bellandi F, et al. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patients' data meta-analysis. Heart 2008; 94: 1548-58
60. Janssens L, Van Haesendonck C, Van Boven AJ, et al. Early treatment of ST elevation myocardial infarction with abciximab or with abciximab and reteplase reduces the incidence of cardiogenic shock: results of the FINESSE trial [abstract]. Eur Heart J 2008; 29 (Suppl.): 136
61. van 't Hof AW, Liem A, de Boer MJ, et al. Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction. Zwolle Myocardial infarction Study Group. Lancet 1997 Aug 30; 350 (9078): 615-9
62. Angeja BG, Gunda M, Murphy SA, et al. TIMI myocardial perfusion grade and ST segment resolution: association with infarct size as assessed by single photon emission computed tomography imaging. Circulation 2002 Jan 22; 105 (3): 282-5
63. De Luca G, Maas AC, van 't Hof AW, et al. Impact of STsegment depression resolution on mortality after successful mechanical reperfusion in patients with ST-segment elevation acute myocardial infarction. Am J Cardiol 2005 Jan 15; 95 (2): 234-6
64. Anderson RD, White HD, Ohman EM, et al. Predicting outcome after thrombolysis in acute myocardial infarction according to ST-segment resolution at 90 minutes: a GUSTO-III trial. Global Use of Strategies To Open occluded coronary arteries. Am Heart J 2002 Jul; 144 (1):81-8
65. Valgimigli M, Campo G, Arcozzi C, et al. Two-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation assisted by systematic glycoprotein IIb/IIIa inhibitor infusion in patients with myocardial infarction: results from the STRATEGY study. J Am Coll Cardiol 2007 Jul 10; 50 (2): 138-45
66. Rao SV, O'Grady K, Pieper KS, et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 2005 Nov 1; 96 (9): 1200-6
67. Stone GW, Bertrand ME, Moses JW, et al. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY timing trial. JAMA 2007 Feb 14; 297 (6): 591-602
68. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008 May 22; 358: 2218-30
69. Berkowitz SD, Harrington RA, Rund MM, et al. Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. Circulation 1997 Feb 18; 95 (4): 809-13
70. Mehilli J, Kastrati A, Huber K, et al. Pretreatment With a High Loading Dose of Clopidogrel and Value of Abciximab During Primary Coronary Intervention in Patients With Acute Myocardial Infarction. Results of the Randomized Bavarian reperfusion alternatives evaluation-3 (BRAVE-3) trial [abstract no. 2404-7]. American College of Cardiology 57th Annual Scientific Sessions; 2008 Mar 29-Apr 1; Chicago (IL)
71. van 't Hof AW. The effect of the pre-hospital initiation of a glycoprotein 2b/3a recepter blocker in patients undergoing primary angioplasty for acute myocardial infarction. Results of the Ongoing Tirofiban in Myocardial Infarction Evaluation (On-TIME) 2 Trial: clinical trial update I [abstract no. 975-976]. European Society of Cardiology Congress; 2008 Aug 30-Sept 3; Munich
72. Thiele H, Schindler K, Friedenberger J, et al. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation 2008 Jul 1; 118 (1): 6-8
73. Montalescot G, Cohen M, Salette G, et al. Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial. Eur Heart J 2008 Feb; 29 (4): 462-71
74. Alexander KP, Chen AY, Roe MT, et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 2005 Dec 28; 294 (24): 3108-16
75. Integrilin [package insert]. Auckland: Schering-Plough, 2006
76. Aggrastat [package insert]. Auckland: Merck Sharp & Dohme (NZ) Ltd, 2001
77. Moliterno D. A randomized, multicenter, double-blind, abciximab-controlled study to evaluate the efficacy of tirofiban versus abciximab among subjects undergoing percutaneous coronary intervention with intracoronary stent placement receiving bivalirudin or heparin [abstract]. Transcatheter Coronary Therapeutics Symposium; 2005 Oct 17-21; Washington, DC
78. Chase AJ, Fretz EB, Warburton WP, et al. Association of the arterial access site at angioplasty with transfusion and mortality: the M.O.R.T.A.L study (Mortality benefit Of Reduced Transfusion after percutaneous coronary intervention via the Arm or Leg). Heart 2008 Aug; 94 (8): 1019-25
79. Wu TG, Zhao Q, Huang WG, et al. Effect of intracoronary tirofiban in patients undergoing percutaneous coronary intervention for acute coronary syndrome. Circulation 2008 Oct; 72 (10): 1605-9